X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4807) 4807
Book Review (546) 546
Publication (336) 336
Magazine Article (17) 17
Conference Proceeding (6) 6
Book Chapter (4) 4
Book / eBook (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4514) 4514
humans (3370) 3370
male (3079) 3079
sildenafil citrate (2143) 2143
animals (1764) 1764
sulfones (1508) 1508
female (1494) 1494
middle aged (1389) 1389
adult (1261) 1261
sulfones - administration & dosage (1231) 1231
sildenafil (1197) 1197
sulfones - pharmacology (1112) 1112
sulfones - therapeutic use (1091) 1091
piperazines - therapeutic use (1047) 1047
purines (1038) 1038
piperazines - administration & dosage (981) 981
aged (928) 928
rats (894) 894
pharmacology & pharmacy (887) 887
erectile dysfunction - drug therapy (791) 791
treatment outcome (761) 761
erectile dysfunction (712) 712
piperazines - pharmacology (711) 711
dose-response relationship, drug (657) 657
urology & nephrology (601) 601
sulfones - adverse effects (581) 581
administration, oral (571) 571
abridged index medicus (554) 554
double-blind method (522) 522
mice (520) 520
phosphodiesterase inhibitors - therapeutic use (508) 508
piperazines - adverse effects (490) 490
purines - administration & dosage (467) 467
purines - therapeutic use (451) 451
impotence (450) 450
vasodilator agents - administration & dosage (422) 422
drug therapy (405) 405
phosphodiesterase inhibitors - administration & dosage (395) 395
time factors (395) 395
vasodilator agents - therapeutic use (377) 377
analysis (372) 372
hypertension, pulmonary - drug therapy (367) 367
purines - pharmacology (361) 361
vardenafil dihydrochloride (348) 348
phosphodiesterase inhibitors - pharmacology (347) 347
cardiac & cardiovascular systems (338) 338
nitric-oxide (335) 335
rofecoxib (332) 332
rats, sprague-dawley (331) 331
drug therapy, combination (313) 313
research (305) 305
disease models, animal (303) 303
efficacy (298) 298
nitric oxide (298) 298
lactones - adverse effects (296) 296
nonsteroidal antiinflammatory drugs (291) 291
care and treatment (286) 286
men (286) 286
celecoxib (281) 281
rats, wistar (280) 280
double-blind (273) 273
lactones - therapeutic use (269) 269
adolescent (268) 268
therapy (264) 264
expression (261) 261
pulmonary hypertension (261) 261
lactones - administration & dosage (260) 260
hypertension (258) 258
risk factors (253) 253
safety (251) 251
medicine, general & internal (250) 250
oral sildenafil (249) 249
phosphodiesterase inhibitors - adverse effects (249) 249
prospective studies (248) 248
sulfones - pharmacokinetics (247) 247
dosage and administration (244) 244
aged, 80 and over (243) 243
tadalafil (242) 242
drug administration schedule (234) 234
medicine & public health (227) 227
pharmacokinetics (223) 223
anti-inflammatory agents, non-steroidal - adverse effects (222) 222
blood pressure - drug effects (217) 217
cox-2 inhibitors (217) 217
oncology (217) 217
health aspects (213) 213
vasodilator agents - pharmacology (211) 211
surgery (207) 207
cross-over studies (204) 204
cyclooxygenase inhibitors - adverse effects (204) 204
erectile dysfunction - etiology (201) 201
cyclooxygenase inhibitors - therapeutic use (195) 195
neurosciences (195) 195
anti-inflammatory agents, non-steroidal - therapeutic use (194) 194
cyclooxygenase 2 (192) 192
inflammation (191) 191
penile erection - drug effects (189) 189
vardenafil (189) 189
drug interactions (188) 188
inhibition (187) 187
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4584) 4584
German (66) 66
Russian (45) 45
French (44) 44
Japanese (18) 18
Spanish (17) 17
Chinese (12) 12
Italian (7) 7
Polish (7) 7
Dutch (5) 5
Swedish (5) 5
Hungarian (4) 4
Norwegian (4) 4
Danish (3) 3
Turkish (3) 3
Portuguese (2) 2
Bulgarian (1) 1
Croatian (1) 1
Hebrew (1) 1
Korean (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 05/2010, Volume 55, Issue 18, pp. 1915 - 1922
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2008, Volume 149, Issue 8, pp. 521 - 530
Background: Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension.... 
INHALED ILOPROST | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ORAL SILDENAFIL | EFFICACY | TREPROSTINIL | SAFETY | COMBINATION THERAPY | PROSTACYCLIN | BOSENTAN | Piperazines - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Sulfones - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Dyspepsia - chemically induced | Purines - administration & dosage | Hemodynamics - physiology | Walking - physiology | Sildenafil Citrate | Time Factors | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Purines - adverse effects | Drug Therapy, Combination | Headache - chemically induced | Double-Blind Method | Administration, Oral | Piperazines - adverse effects | Antihypertensive Agents - adverse effects | Adolescent | Quality of Life | Aged | Vasodilator Agents - adverse effects | Hypertension, Pulmonary - etiology | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Complications and side effects | Epoprostenol | Dosage and administration | Sildenafil | Drug therapy, Combination | Research | Drug therapy | Pulmonary hypertension | Hypertension | Inhibitor drugs | Patients | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9824, pp. 1403 - 1411
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 07/2007, Volume 6, Issue 7, pp. 2012 - 2021
With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy... 
kinase inhibitor | Pharmacodynamics | pazopanib | angiogenesis | VEGF | TARGET | ONCOLOGY | FACTOR RECEPTORS | EXPRESSION | CANCER | TUMORS | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Pyrimidines - blood | Humans | Fibroblast Growth Factor 2 - pharmacology | Antineoplastic Agents - administration & dosage | Indazoles - administration & dosage | Sulfones - pharmacology | Neovascularization, Pathologic - pathology | Phosphotyrosine - metabolism | Dose-Response Relationship, Drug | Sulfonamides - blood | Inhibitory Concentration 50 | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cornea - pathology | Phosphorylation - drug effects | Sulfones - blood | Vascular Endothelial Growth Factor A - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Pyrimidines - pharmacology | Sulfones - pharmacokinetics | Sulfonamides - pharmacology | Protein Kinase Inhibitors - blood | Sulfonamides - pharmacokinetics | Indazoles - pharmacology | Protein Kinase Inhibitors - administration & dosage | Indazoles - blood | Animals | Indazoles - pharmacokinetics | Cell-Free System | Mice, Nude | Antineoplastic Agents - blood | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Mice | Protein Kinase Inhibitors - pharmacology | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Index Medicus
Journal Article
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 11/2012, Volume 157, Issue 10, pp. 681 - 691
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2013, Volume 19, Issue 6, pp. 1512 - 1524
Journal Article
Circulation, ISSN 0009-7322, 05/2014, Volume 129, Issue 19, pp. 1914 - 1923
Journal Article